Table 2 Demographic and clinical features of the evaluated patients stratified according the different outcomes

Number of patients

100

29

22

33

16

Female/Male

66/34

20/9

12/10

12/11

12/4

Age (years), mean ± SD

45.35 ± 16.23

49.31 ± 12.47

43.81 ± 15.13

40.24 ± 15.86

50.81 ± 19.97

 Fever, n (%)

100 (100)

29 (100)

22 (100)

33 (100)

16 (100)

 Weight loss, n (%)

5 (5)

1 (3.44)

2 (9.10)

0

2 (12.5)

 Rash, n (%)

78 (78)

24 (82.75)

14 (48.27)

28 (84.84)

12 (75)

 Joints involvement, n (%)

86 (86)

27 (93.10)

21 (95.45)

26 (78.79)

12 (75)

 Sore throat, n (%)

64 (64)

10 (34.48)

13 (59.10)

25 (75.76)

16 (100)

 Myalgia, n (%)

57 (57)

12 (41.37)

15 (68.19)

16 (48.49)

14 (87.5)

 Lymphadenopathy, n (%)

57 (57)

11 (37.93)

16 (72.72)

15 (45.45)

15 (93.75)

 Splenomegaly, n (%)

79 (79)

22 (75.86)

20 (90.91)

23 (69.70)

14 (87.5)

 Hepatic involvement, n (%)

62 (62)

18 (62.07)

16 (72.72)

18 (54.54)

10 (62.5)

 Pleurisy, n (%)

14 (14)

1 (3.44)

5 (22.72)

4 (12.12)

4 (25)

 Lung involvement, n (%)

13(13)

2 (6.89)

3 (13.63)

1 (3.03)

7 (43.75)

 Pericarditis, n (%)

15 (15)

1 (3.44)

3 (13.63)

6 (18.18)

5 (31.25)

 Abdominal pain, n (%)

18 (18)

2 (6.89)

4 (18.19)

7 (21.21)

5 (31.25)

 Systemic score, mean ± SD

6.11 ± 2.02

4.93 ± 1.79

6.41 ± 2.05

6.12 ± 1.66

7.81 ± 1.54

 Comorbidities, n (%)

33 (33)

6 (20.68)

8 (36.36)

9 (27.28)

10 (62.5)

 Leukocytosis > 15,000/mm³, n (%)

36 (36)

4 (13.79)

7 (31.82)

19 (57.57)

6 (37.5)

 Serum ferritin (ng/mL), mean ± SD

2560.07 ± 3726.64

1634.82 ± 1198.92

2541.04 ± 3028.16

2886.09 ± 5438.65

3560.94 ± 3004.93

 ESR (mm/hour), mean ± SD

67.28 ± 26.65

68.93 ± 23.94

61.81 ± 26.84

65.18 ± 26.77

74.93 ± 28.29

 CRP (mg/L), mean ± SD

78.35 ± 72.76

83.83 ± 70.38

48.34 ± 35.64

72.16 ± 83.47

111.37 ± 61.76

 MAS

13 (13)

0

3 (13.63)

0

10 (62.5)

 Kidney failure

2 (2)

0

0

0

2 (12.5)

 Myocarditis

1 (1)

1 (3.44)

0

0

0

 Low dosage of steroid monotherapy, n (%)

4 (4)

0

0

4 (12.12)

0

 High dosage steroid monotherapy, n (%)

39 (39)

24 (79.31)

2 (9.1)

7 (21.21)

6 (93.75)

 High dosage steroid pulse therapy (500–1000 mg), n (%)

37 (37)

10 (34.48)

9 (40.91)

5 (15.15)

13 (81.25)

 sDMARD(s)

55 (55)

5 (17.24)

18 (81.82)

22 (66.67)

10 (62.5)

 Combination therapy, steroids + sDMARD(s), n (%)

25 (25)

5 (17.24)

8 (36.36)

10 (30.3)

2 (12.5)

 Combination therapy, steroids + biologics agent ± sDMARD(s), n (%)

32 (32)

0

12 (54.55)

12 (36.37)

8 (50)